$4.29
-0.04 (-0.92%)
Open$4.32
Previous Close$4.33
Day High$4.39
Day Low$4.29
52W High$7.54
52W Low$3.93
Volume—
Avg Volume1.79M
Market Cap247.02M
P/E Ratio3.47
EPS$0.93
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+228.4% upside
Current
$4.29
$4.29
Target
$14.09
$14.09
$7.81
$14.09 avg
$15.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.88M | 3.05M | 39.71M |
| Net Income | 59.75M | 33.52M | -4,431,314 |
| Profit Margin | 1,223.1% | 1,161.9% | -11.2% |
| EBITDA | 60.45M | 35.80M | -4,969,444 |
| Free Cash Flow | — | — | -4,447,710 |
| Rev Growth | +60.4% | +60.4% | +12.5% |
| Debt/Equity | 0.13 | 0.13 | 0.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |